CLOs on the Move

Armetheon

www.armetheon.com

 
Armetheon, Inc. is a privately held San Francisco Bay area-based biopharmaceutical company with late-stage clinical drug candidates in development for cardiovascular diseases. The company was founded in 2011 by experienced biotech entrepreneurs and drug developers. Armetheon’s two late-stage small molecule drug candidates are for use in the areas of oral anti-coagulation and anti-arrhythmia for atrial fibrillation. The company was founded with the idea that drug innovations can happen by building on the success of proven medications. We create solutions that are within the same class of medication and that utilize the same mechanism of action as existing therapies. This development approach has the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.armetheon.com
  • 3375 Scott Blvd Suite 306
    Santa Clara, CA USA 95054
  • Phone: 650.646.3898

Executives

Name Title Contact Details

Similar Companies

Nationwide Medical

Nationwide Medical is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ulab Systems

uLab has innovated the next generation of smile technology. Create aligner movement plans in as little as 10 minutes and print custom aligners the same day, right in your office.

Micropulse Inc

Micropulse, Inc., located 30 miles east of the Orthopaedic Capital of the World, has been serving the Medical Device Industry as a manufacturer of orthopaedic instruments and implants since 1988. Although Micropulse was founded as a precision tooling

Community Products

Community Products is a Rifton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seno Medical Instruments

Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Seno`s Imagio breast imaging system fuses opto-acoustic technology with ultrasound to generate functional and anatomical images of the breast. The opto-acoustic images provide a unique blood map in and around suspicious breast masses while the ultrasound provides a traditional anatomic image. Through the appearance or absence of the two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno believes that the Imagio OA breast imaging system will be a more effective tool to help radiologists confirm or rule out malignancy than current diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents.